Trial Profile

Single agent chemotherapy with weekly docetaxel vs combination chemotherapy in second-line treatment of advanced non small cell lung cancer

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Capecitabine; Gemcitabine; Vinorelbine
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms DISTAL-2

Most Recent Events

01 Feb 2009 Primary endpoint 'overall Survival duration' has not been met.
01 Feb 2009 Results reported in Lung Cancer.
26 May 2008 Results presented at ASCO 2008.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com